Cargando…
Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555261/ https://www.ncbi.nlm.nih.gov/pubmed/32847118 http://dx.doi.org/10.3390/diagnostics10090629 |
_version_ | 1783593966577385472 |
---|---|
author | Iluta, Sabina Termure, Dragos-Alexandru Petrushev, Bobe Fetica, Bogdan Badea, Mindra-Eugenia Moldovan-Lazar, Madalina Lenghel, Manuela Csutak, Csaba Roman, Andrei Pasca, Sergiu Zimta, Alina-Andreea Jitaru, Ciprian Tomuleasa, Ciprian Roman, Rares-Calin |
author_facet | Iluta, Sabina Termure, Dragos-Alexandru Petrushev, Bobe Fetica, Bogdan Badea, Mindra-Eugenia Moldovan-Lazar, Madalina Lenghel, Manuela Csutak, Csaba Roman, Andrei Pasca, Sergiu Zimta, Alina-Andreea Jitaru, Ciprian Tomuleasa, Ciprian Roman, Rares-Calin |
author_sort | Iluta, Sabina |
collection | PubMed |
description | Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options. |
format | Online Article Text |
id | pubmed-7555261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75552612020-10-19 Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP Iluta, Sabina Termure, Dragos-Alexandru Petrushev, Bobe Fetica, Bogdan Badea, Mindra-Eugenia Moldovan-Lazar, Madalina Lenghel, Manuela Csutak, Csaba Roman, Andrei Pasca, Sergiu Zimta, Alina-Andreea Jitaru, Ciprian Tomuleasa, Ciprian Roman, Rares-Calin Diagnostics (Basel) Case Report Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options. MDPI 2020-08-24 /pmc/articles/PMC7555261/ /pubmed/32847118 http://dx.doi.org/10.3390/diagnostics10090629 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Iluta, Sabina Termure, Dragos-Alexandru Petrushev, Bobe Fetica, Bogdan Badea, Mindra-Eugenia Moldovan-Lazar, Madalina Lenghel, Manuela Csutak, Csaba Roman, Andrei Pasca, Sergiu Zimta, Alina-Andreea Jitaru, Ciprian Tomuleasa, Ciprian Roman, Rares-Calin Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP |
title | Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP |
title_full | Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP |
title_fullStr | Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP |
title_full_unstemmed | Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP |
title_short | Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP |
title_sort | clinical remission in a 72-year-old patient with a massive primary cutaneous peripheral t-cell lymphoma-nos of the eyelid, following combination chemotherapy with etoposide plus cop |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555261/ https://www.ncbi.nlm.nih.gov/pubmed/32847118 http://dx.doi.org/10.3390/diagnostics10090629 |
work_keys_str_mv | AT ilutasabina clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT termuredragosalexandru clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT petrushevbobe clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT feticabogdan clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT badeamindraeugenia clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT moldovanlazarmadalina clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT lenghelmanuela clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT csutakcsaba clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT romanandrei clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT pascasergiu clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT zimtaalinaandreea clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT jitaruciprian clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT tomuleasaciprian clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop AT romanrarescalin clinicalremissionina72yearoldpatientwithamassiveprimarycutaneousperipheraltcelllymphomanosoftheeyelidfollowingcombinationchemotherapywithetoposidepluscop |